PMID- 7540478
OWN - NLM
STAT- MEDLINE
DCOM- 19950726
LR  - 20220311
IS  - 0804-4643 (Print)
IS  - 0804-4643 (Linking)
VI  - 132
IP  - 6
DP  - 1995 Jun
TI  - Growth hormone treatment during pregnancy in a growth hormone-deficient woman.
PG  - 727-9
AB  - Information on the course and outcome of pregnancies in growth hormone 
      (GH)-deficient patients is sparse, and GH treatment during pregnancy in such 
      women has not been described previously. We have studied fetal growth and serum 
      levels of GH, insulin-like growth factor I (IGF-I) and IGF binding protein 3 
      (IGFBP-3) during pregnancy, as well as birth weight and hormone levels after 
      delivery in a 25-year-old woman with idiopathic, isolated GH deficiency diagnosed 
      at the age of 7 years. As part of a clinical trial, the patient was treated with 
      2 IU/M2 GH for a period of 5 years. At this time she became pregnant after donor 
      insemination. The GH treatment was continued until variant GH production from the 
      placenta was evident. Serum levels of GH, IGF-I and IGFBP-3 were measured monthly 
      during pregnancy after 3 days off GH therapy. Abdominal ultrasound was performed 
      five times. Hormonal levels were measured immediately after delivery and during 
      the following days. Serum GH and IGF-I levels increased during the second half of 
      pregnancy; serum IGFBP-3 remained constant throughout pregnancy at a normal 
      level. Serum levels of GH fell within 1 h after delivery, and levels of IGF-I and 
      IGFBP-3 decreased into the range of GH-deficient women 4 days after. The fetal 
      biparietal diameter increased normally, and birthweight was 3.564 kg, length 52 
      cm. No adverse events were recorded. We conclude that the role of GH replacement 
      during pregnancy of GH-deficient women should be investigated further.
FAU - Muller, J
AU  - Muller J
AD  - Department of Growth and Reproduction, Rigshospitalet, Copenhagen, Denmark.
FAU - Starup, J
AU  - Starup J
FAU - Christiansen, J S
AU  - Christiansen JS
FAU - Jorgensen, J O
AU  - Jorgensen JO
FAU - Juul, A
AU  - Juul A
FAU - Skakkebaek, N E
AU  - Skakkebaek NE
LA  - eng
PT  - Case Reports
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Eur J Endocrinol
JT  - European journal of endocrinology
JID - 9423848
RN  - 0 (Carrier Proteins)
RN  - 0 (Insulin-Like Growth Factor Binding Proteins)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 9002-72-6 (Growth Hormone)
SB  - IM
MH  - Adult
MH  - Carrier Proteins/blood
MH  - Double-Blind Method
MH  - Embryonic and Fetal Development
MH  - Female
MH  - Growth Hormone/blood/*deficiency/*therapeutic use
MH  - Humans
MH  - Infant, Newborn
MH  - Insulin-Like Growth Factor Binding Proteins
MH  - Insulin-Like Growth Factor I/metabolism
MH  - Pregnancy
MH  - Pregnancy Complications/blood/*drug therapy
MH  - Pregnancy Outcome
EDAT- 1995/06/01 00:00
MHDA- 1995/06/01 00:01
CRDT- 1995/06/01 00:00
PHST- 1995/06/01 00:00 [pubmed]
PHST- 1995/06/01 00:01 [medline]
PHST- 1995/06/01 00:00 [entrez]
AID - 10.1530/eje.0.1320727 [doi]
PST - ppublish
SO  - Eur J Endocrinol. 1995 Jun;132(6):727-9. doi: 10.1530/eje.0.1320727.